

Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



30th October 2018

To,

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051

Scrip Code : 524518

Name of Scrip : KREBSBIO

Dear Sir / Madam,

Sub : Outcome of Board Meeting

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 [“SEBI LODR Regulations”], we wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. October 30, 2018 :

- (a) The unaudited financial results for the quarter and half year ended 30th September 2018 along with the Limited Review Report thereon (Enclosed herewith).


Kindly note that the meeting was commenced at 10:30 AM and concluded at 01:10PM.

You are requested to take note of the above.

Thanking you,

Yours faithfully,

For Krebs Biochemicals & Industries Limited


Haritha Varanasi
Company Secretary

KREBS BIOCHEMICALS & INDUSTRIES LIMITED

CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Ankapalli, Visakhapatnam, Andhra Pradesh - 531 031

Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No:8, Banjara Hills, Hyderabad - 500 034



STANDALONE FINANCIAL RESULTS FOR THE QUARTER / PERIOD ENDED 30TH SEPTEMBER 2018

(Rs. In lacs)

Sl.No	Particulars	Quarter Ended			Half Year Ended		For The
		30.09.2018 (Un Audited)	30.06.2018 (Un Audited)	30.09.2017 (Un Audited)	30.09.2018 (Un Audited)	30.09.2017 (Un Audited)	Year Ended 31.03.2018 (Audited)
PART - 1							
1	Revenue from Operations						
	a) Net Sales/Income from Operations	1,272.13	654.74	261.36	1,926.87	337.74	2538.24
	b) Other Operating Income	303.59	239.93	39.00	543.52	78.00	839.67
2	Other Income	1.47	3.00	-	4.47	4.03	20.61
3	Total Income (1+2)	1,577.19	897.67	300.36	2,474.86	419.77	3,398.52
4	Expenses						
	a) Cost of Material Consumed	845.61	114.28	184.47	959.89	214.87	1,712.36
	b) Changes in inventories of finished goods, work-in-progress	(115.54)	339.21	(100.01)	223.67	(89.92)	(441.83)
	c) Employee benefits expense	353.24	340.03	173.30	693.27	323.70	1,148.53
	d) Finance Costs	145.74	142.40	124.41	288.14	234.60	516.52
	e) Depreciation and Amortisation expense	107.37	107.37	101.85	214.74	203.71	414.97
	f) Other Manufacturing Expenses	453.58	304.49	199.68	758.07	411.03	1,320.57
	g) Other Expenses	94.59	76.39	102.68	170.98	182.19	388.46
	Total Expenses (4)	1,884.59	1,424.17	786.38	3,308.76	1,480.19	5,059.58
5	Profit / (Loss) before exceptional items and tax (3±4)	(307.40)	(526.50)	(486.03)	(833.90)	(1,060.42)	(1,661.06)
6	Exceptional Items:						
	a) Depletion in Value of Inventory	-	-	-	-	(22.52)	(95.35)
	b) Amounts Written Back	-	-	-	-	-	(0.89)
	c) Prior Period Income/(Expenditure)	-	-	-	-	3.56	(40.03)
	d) Profit on sale of Fixed Assets	-	-	-	-	-	14.83
7	Profit / (Loss) before Tax (5±6)	(307.40)	(526.50)	(486.03)	(833.90)	(1,079.38)	(1,782.49)
8	Tax Expense						
	a) Current Tax	-	-	-	-	-	-
	b) Deferred Tax	-	-	-	-	-	-
9	Profit / (Loss) for the period (7±8)	(307.40)	(526.50)	(486.03)	(833.90)	(1,079.38)	(1,782.49)
10	Other Comprehensive Income	(25.43)	(26.59)	(22.05)	(52.02)	(43.25)	(143.12)
11	Total Comprehensive Income for the period(9±10) (Comprising Profit (Loss) and other Comprehensive Income for the period)	(332.83)	(553.09)	(508.08)	(885.92)	(1,122.63)	(1,925.61)
12	Paid-up equity share capital (Face value of Rs 10/- each)	1,374.43	1,374.43	1,374.43	1,374.43	1,374.43	1,374.43
13	Other Equity						(3,152.35)
14	Earning Per Share (of Rs.10/- each) (not Annualised)						
	(a) Basic	(2.42)	(4.02)	(3.70)	(6.44)	(8.17)	(14.01)
	(b) Diluted	(2.42)	(4.02)	(3.70)	(6.44)	(8.17)	(14.01)
	<i>See accompanying notes to the Financial results</i>						

- The above results have been reviewed by the Audit Committee at its meeting held on 30th October, 2018 and approved by the Board of Directors of the Company at its meeting held on 30th October, 2018. The results are subjected to limited review by statutory Auditors.
- The Company is operating in one segment only hence no segment results have been disclosed.
- Post implementation of GST wef 1st July 2017, revenues are disclosed net of GST. Revenue for the period prior to 1st July 2017 included excise duty which is now subsumed in GST. Accordingly, revenue for the half year ended 30th September 2017 and year ended 31st March 2018 are not comparable with those of the other periods presented.
- The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015.

Place: Hyderabad
Date: 30.10.2018



AVINASH RAVI
 Managing Director
 DIN: 01616152

KREBS BIOCHEMICALS & INDUSTRIES LIMITED

CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031

Corp Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No:8, Banjara Hills, Hyderabad - 500 034


Statement of Assets and Liabilities

(Rs. In laes)

Particulars	As at	As at
	30.09.2018	31.03.20 18
	(Un Audited)	(Audited)
ASSETS		
Non Current Assets		
Property, Plant and Equipment	9,688.44	9,892.99
Capital Work in Progress	312.23	218.94
Other Intangible Assets	344.03	338.57
Financial Assets	137.33	109.90
Other Non Current Assets	401.07	303.33
Total Non Current Assets	10,883.10	10,863.73
Current Assets		
Inventories	803.94	1,172.84
Financial Assets		
Trade Receivables	179.48	32.48
Cash & Cash Equivalents	5.01	41.84
Other Financial Assets	23.87	33.51
Other Current Assets	436.02	443.19
Total Current Assets	1,448.32	1,723.86
Total Assets	12,331.42	12,587.59
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	1,374.43	1,374.43
Other Equity	(4,038.27)	(3,152.35)
Total Equity	(2,663.84)	(1,777.92)
Non Current Liabilities		
Financial Liabilities		
Long Term Borrowings	5,095.01	5,166.17
Provisions	378.83	368.33
Other Non Current Liabilities	4,359.01	4,333.04
Total Non Current Liabilities	9,832.85	9,867.54
Current Liabilities		
Financial Liabilities		
Trade Payables	1,901.29	1,776.00
Other Current Liabilities	3,121.15	2,596.52
Provisions	139.97	125.45
Total Current Liabilities	5,162.41	4,497.97
Total Equity and Liabilities	12,331.42	12,587.59

Place: Hyderabad

Date: 30.10.2018


 AVINASH RAVI
 Managing Director
 DIN: 01616152



PAVULURI & Co.

CHARTERED ACCOUNTANTS


Plot No.48, Flat No.301,
Sucasa, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639 / 2640
Email : pavuluriandco@gmail.com

Limited Review Report

**Review Report to
The Board of Directors,
KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

- a) We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. KREBS BIOCHEMICALS & INDUSTRIES LIMITED** ("the company") for the quarter ended **30th September, 2018** and the year to date from 1st April 2018 to 30th September 2018 (the "Statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with SEBI circular No CIR/CFD/FAC/62/2016 dated 5th July 2016.
- b) The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.
- c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other recognized accounting practices and policies has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For PAVULURI & Co.
Chartered Accountants
Firm Regn. No: 012194S**


**(CA. N. RAJESH)
PARTNER
M.No: 223169**



Place: Hyderabad
Date: 30.10.2018